By Colin Kellaher
Aldeyra Therapeutics has once again filed for Food and Drug Administration of its proposed reproxalap drug candidate for the treatment of signs and symptoms of dry-eye disease.
Aldeyra on Thursday said the resubmission includes results from a recently completed symptom trial the FDA requested late last year when the agency's turned away the Lexington, Mass., company's initial application.
The resubmission also includes a draft label reflecting acute activity in reducing dry-eye symptoms in a dry-eye chamber trial, chronic activity in reducing dry-eye symptoms in a field trial and acute activity in reducing ocular redness in two dry-eye chamber trials.
FDA guidelines call for an acknowledgment of acceptance for review within 30 days of a resubmission and completion of a review within six months.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 03, 2024 08:27 ET (12:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.